Vaccin Genhevac B Pasteur
Indolent B-Cell Non-Hodgkin Lymphoma
Explore 38 assets in Indolent B-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Central Hospital, Nancy, France
Modality
vaccine
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01698866CT.gov Low Grade Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Indolent B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vaccin Genhevac B Pasteur (this asset) | Central Hospital, Nancy, France | Approved | BB · 65 |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Pembrolizumab | University of Washington | P2 | BB |
| Rituximab | Fox Chase Cancer Center | P3 | BB |
| Ibrutinib | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Acalabrutinib | Emory University | P2 | BB |
| Lenalidomide | Antengene Corporation | P2 | BB |
+42 more in the Indolent B-Cell Non-Hodgkin Lymphoma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vaccin Genhevac B Pasteur in Indolent B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vaccin-genhevac-b-pasteur-indolent-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →